TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

IMPLANON

ETONOGESTREL
Approved 2006-07-17
3
Indications
--
Phase 3 Trials
19
Years on Market

Details

Status
Discontinued
First Approved
2006-07-17
Routes
IMPLANTATION
Dosage Forms
IMPLANT

Companies

Active Ingredient: ETONOGESTREL

IMPLANON Approval History

Loading approval history...

What IMPLANON Treats

3 FDA approvals

Originally approved for its first indication in 2006 . Covers 3 distinct patient populations.

  • Other (3)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IMPLANON FDA Label Details

Pro

IMPLANON Patents & Exclusivity

Latest Patent: Jul 2030

Patents (5 active)

US9757552 Expires Jul 28, 2030
US8722037 Expires Sep 28, 2027
US10821277 Expires May 31, 2027
US8888745 Expires Aug 28, 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.